Galapagos, MorphoSys, GlaxoSmithKline deal

Galapagos and MorphoSys added a fourth antibody target to a 2008 deal to discover and co-develop antibodies to treat joint and bone diseases. Galapagos is using its adenoviral target discovery platform to provide antibody targets and MorphoSys is using its HuCAL antibody technology to produce human antibodies against the targets. Antibodies to the first target have been generated and are in disease-specific in vitro and in vivo testing. The partners share development costs and revenues equally up to Phase IIa testing, after which they plan to out-license the antibodies (see BioCentury, Dec. 8, 2008). ...